Welcome to our dedicated page for ARCELLX news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on ARCELLX stock.
Arcellx Inc. (ACLX) is a clinical-stage biotechnology company pioneering controllable cell therapies for cancer and complex diseases. This page aggregates official press releases and verified news about ACLX's immunotherapy advancements, clinical trial progress, and regulatory developments.
Investors and researchers will find timely updates on key milestones including trial results, partnership announcements, and FDA communications. Our curated collection spans therapeutic innovations in multiple myeloma, acute myeloid leukemia, and emerging cell therapy platforms.
All content is sourced directly from company filings and reputable financial publications. Bookmark this page for centralized access to ACLX's latest scientific breakthroughs and strategic business decisions in the evolving cell therapy landscape.
Arcellx (NASDAQ: ACLX) announced clinical data from its Phase 1 and iMMagine-1 studies for anitocabtagene autoleucel (anito-cel) in relapsed/refractory multiple myeloma patients. The Phase 1 study showed a 30.2-month median progression-free survival with 38.1 months median follow-up. The Phase 2 iMMagine-1 study demonstrated 95% overall response rate and 62% complete response rate in 58 patients at 10.3 months median follow-up. No delayed neurotoxicities were observed in over 140 patients across both studies. The company also reported the first patient dosing in the iMMagine-3 study, manufactured by Kite.
Arcellx (NASDAQ: ACLX) reported its Q2 2024 financial results and business updates. Key highlights include:
- Earned a $68M milestone payment from Kite for iMMagine-1 enrollment
- Submitted an abstract for iMMagine-1 study at the 66th ASH Annual Meeting
- Kite initiated the global Phase 3 trial, iMMagine-3
- FDA cleared anito-cel IND application for myasthenia gravis
Financial highlights:
- Cash position: $646.8M, funding operations into 2027
- Collaboration revenue: $27.4M, up from $14.3M in Q2 2023
- R&D expenses: $41.0M, up from $28.3M in Q2 2023
- G&A expenses: $21.4M, up from $15.5M in Q2 2023
- Net loss: $27.2M, compared to $23.9M in Q2 2023
Arcellx and Kite, in partnership with Gilead Company, announced updates on their anitocabtagene autoleucel (anito-cel) multiple myeloma program. The global Phase 3 trial, iMMagine-3, will evaluate anito-cel in patients with relapsed and/or refractory multiple myeloma exposed to specific previous treatments. The technical transfer for manufacturing anito-cel is complete, and preliminary data from the iMMagine-1 trial is expected by year-end.
Kite, a Gilead Company, and Arcellx, Inc. announced operational updates on their anito-cel multiple myeloma program. They shared the iMMagine-3 trial design, manufacturing details, and plans to present data from the iMMagine-1 trial. Anito-cel is a BCMA CAR T cell therapy for relapsed/refractory multiple myeloma.
Arcellx, Inc. (NASDAQ: ACLX) reported financial highlights for Q1 2024, with $691.0 million in cash, collaboration revenue of $39.3 million, R&D expenses down by $0.6 million, G&A expenses up by $7.3 million, and a net loss of $7.2 million.
Arcellx, a biotechnology company focused on innovative immunotherapies for cancer, will participate in two upcoming investor conferences: BofA Securities Health Care Conference 2024 and TD Cowen 5th Annual Oncology Innovation Summit. The company aims to enhance its investor relations through these engagements.
FAQ
What is the current stock price of ARCELLX (ACLX)?
What is the market cap of ARCELLX (ACLX)?
